SBI Securities Co. Ltd. Purchases 108,670 Shares of Gyre Therapeutics, Inc. $GYRE

SBI Securities Co. Ltd. increased its holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 87.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 232,299 shares of the company’s stock after buying an additional 108,670 shares during the period. SBI Securities Co. Ltd. owned 0.25% of Gyre Therapeutics worth $1,707,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares in the last quarter. Advantage Alpha Capital Partners LP increased its position in shares of Gyre Therapeutics by 54.0% in the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after purchasing an additional 4,790 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Gyre Therapeutics by 18.7% in the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock valued at $127,000 after purchasing an additional 2,596 shares in the last quarter. Finally, American Century Companies Inc. purchased a new stake in Gyre Therapeutics in the first quarter valued at approximately $184,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GYRE shares. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Wednesday, October 8th. HC Wainwright initiated coverage on Gyre Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $18.00 price objective on the stock. Jefferies Financial Group started coverage on Gyre Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 16th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Gyre Therapeutics currently has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Price Performance

GYRE opened at $8.34 on Thursday. The stock’s 50 day simple moving average is $7.74 and its 200 day simple moving average is $8.11. The firm has a market cap of $803.25 million, a price-to-earnings ratio of 834.83 and a beta of 1.88. Gyre Therapeutics, Inc. has a 1 year low of $6.11 and a 1 year high of $16.06.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Monday, August 11th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%. The company had revenue of $26.77 million for the quarter, compared to analysts’ expectations of $30.80 million.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.